SAN JOSE, Calif., May 26, 2021 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer and infectious diseases,
announced today that its ovarian cancer vaccine technology is part
of an award from the National Cancer Institute (NCI). Anixa
Biosciences holds an exclusive worldwide license from Cleveland
Clinic for this vaccine technology.
The award from the NCI, part of the National Institutes of
Health, was made to Cleveland Clinic through the NCI-PREVENT
program.
The PREVENT program is a peer-reviewed agent development
program designed to support preclinical development of innovative
interventions and biomarkers for cancer prevention and interception
towards clinical trials. The scientific and financial
resources of the PREVENT program will be allocated to four
general milestones as follows:
- Milestone 1: Immunogenicity and efficacy testing of the
vaccine in mouse model
- Milestone 2: Development of the expression vector for
optimal vaccine production
- Milestone 3: cGMP (current Good Manufacturing Practice)
manufacturing of vaccine and pre-IND (Investigational New Drug)
meeting with the US Food and Drug Administration
- Milestone 4: IND enabling cGLP (current Good Laboratory
Practice) studies and IND filing
All of this work will be performed at NCI facilities, by NCI
scientific staff with NCI financial resources. Milestone 1
will begin shortly after execution of contracts and design of
experiments. Milestones 2-4 will be performed successively as
progress is achieved.
The technology subject to the application titled,
Immunoprevention of Human Epithelial Ovarian Carcinoma
(EOC), was invented by a research team led by Dr. Vincent Tuohy of Cleveland Clinic's Lerner
Research Institute. Dr. Tuohy stated, "This peer-reviewed
collaboration will provide us the vast laboratory and financial
resources of the NCI to aid in the development of our
vaccine. Our vision with this technology is to eliminate
ovarian cancer worldwide, especially since women who suffer from
ovarian cancer tend to have poor outcomes."
Dr. Amit Kumar, President and CEO
of Anixa Biosciences, stated, "This technology along with Dr.
Tuohy's breast cancer vaccine have the potential to eliminate two
of the most common malignancies in women. We continue to be pleased
to be collaborating on these programs."
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutics portfolio includes a cancer immunotherapy program
which uses a novel type of CAR-T, known as chimeric endocrine
receptor T-cell (CER-T) technology, and a Covid-19 therapeutics
program focused on inhibiting certain viral protein function. The
company's vaccine portfolio includes a vaccine to prevent breast
cancer, and specifically triple negative breast cancer (TNBC), the
most deadly form of the disease, and a vaccine to prevent ovarian
cancer. These vaccine technologies focus on immunizing against
specific proteins that have been found to be expressed in certain
forms of cancer. Anixa continually examines emerging technologies
in complementary fields for further development and
commercialization. Additional information is available at
www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not statements
of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We generally use
the words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-support-from-the-national-cancer-institute-for-ovarian-cancer-vaccine-developed-by-cleveland-clinic-301299633.html
SOURCE Anixa Biosciences, Inc.